KR950031101A - Angiogenesis promoter composition - Google Patents

Angiogenesis promoter composition Download PDF

Info

Publication number
KR950031101A
KR950031101A KR1019940010142A KR19940010142A KR950031101A KR 950031101 A KR950031101 A KR 950031101A KR 1019940010142 A KR1019940010142 A KR 1019940010142A KR 19940010142 A KR19940010142 A KR 19940010142A KR 950031101 A KR950031101 A KR 950031101A
Authority
KR
South Korea
Prior art keywords
fraction
angiogenesis
composition according
aloe
promoter composition
Prior art date
Application number
KR1019940010142A
Other languages
Korean (ko)
Other versions
KR0156593B1 (en
Inventor
김경호
박정일
성충기
김진웅
최재수
이승기
김영식
손병화
정명희
박영인
김규원
이종길
Original Assignee
이연호
주식회사 남양알로에
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이연호, 주식회사 남양알로에 filed Critical 이연호
Priority to KR1019940010142A priority Critical patent/KR0156593B1/en
Publication of KR950031101A publication Critical patent/KR950031101A/en
Application granted granted Critical
Publication of KR0156593B1 publication Critical patent/KR0156593B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 알로에의 글리코펩타이드 및 저분자물질 분획인 G1G1 분획을 함유하는 혈관생성촉진제 조성물에 관한 것이다. 본 발명에 따르는 알로에의 글리코펩타이드 및 저분자물질 G1G1 분획은 알로에의 전체 잎의 외피를 제거하여 겔 분획만을 분리하고, 겔 분획을 동결건조시킨 후, 증류수에 용해시키고, 메탄올, 에탄올, 프로판올, 부탄올등의 탄소수 1 내지 4의 알콜을 가하여 정치시키고 원심분리하여 침전을 제거한 후, 상등액으로부터 에탄올을 증발시켜 제거하고 잔류물을 동결건조시킴을 특징으로 하는 방법에 의해 수득된다. 알로에의 글리코펩타이드 및 저분자물질 G1G1분획을 함유하는 본 발명의 혈관생성촉진제 조성물은 강력한 혈관생성촉진효과를 나타내어 창상부위나 수술부위 등의 회복을 위해 특히 외과적 영역에서 바람직하게 사용될 수 있다.The present invention relates to an angiogenesis composition comprising a glycopeptide of Aloe and a G1G1 fraction which is a low molecular weight fraction. Glycopeptide and low molecular weight G1G1 fraction of aloe according to the present invention is removed from the outer skin of the aloe, only the gel fraction is separated, the gel fraction is lyophilized, dissolved in distilled water, methanol, ethanol, propanol, butanol and the like It is obtained by a method characterized by adding an alcohol having 1 to 4 carbon atoms, leaving it to stand and centrifuging to remove the precipitate, and then removing the ethanol from the supernatant by removing the residue and freeze-drying the residue. Angiogenesis composition of the present invention containing glycopeptide and low molecular weight G1G1 fraction of aloe has a powerful angiogenesis-promoting effect and can be preferably used in the surgical area, especially for recovery of wounds and surgical sites.

Description

혈관형성 촉진제 조성물Angiogenesis promoter composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 실험예 1에서 CAM 시험방법에 따라 본 발명의 G1G1분획에 대한 대조용으로 사용된 각각의 화합물로 처리한 계배의 융모요막에서의 혈관형성작용을 나타낸 사진이다.〔1: 공시험용 대조군, 2: 덱사메타존 처리군, 3: 오카다산 처리군, 4: PMA 처리군〕, 제2도는 실험예 1에서 CAM 시험방법에 따라 계배를 알로에의 G1분획(2) 또는 G1G1분획(3)으로 처리한 경우의 혈관형성효과를 대조군(1)의 경우와 비교하여 나타낸 사진이다.FIG. 1 is a photograph showing angiogenic activity in the chorionic villus of chicks treated with each compound used as a control for the G1G1 fraction of the present invention according to the CAM test method in Experimental Example 1. , 2: dexamethasone treated group, 3: Okadaic acid treated group, 4: PMA treated group], FIG. 2 shows G1 fraction (2) or G1G1 fraction (3) of aloe in Experimental Example 1 according to the CAM test method. Angiogenesis effect when treated with a photo is shown compared with the case of the control (1).

Claims (10)

알로에의 글리코펩타이드 및 저분자물질 분획인 G1G1 분획을 함유함을 특징으로 하는 혈관생성촉진제 조성물,Angiogenesis promoter composition comprising the glycopeptide of Aloe and G1G1 fraction which is a low molecular weight fraction, 제1항에 있어서, 추가로 하나 또는 그 이상의 약제학적으로 허용되는 담체를 함유하는 혈관생성촉진제 조성물.The angiogenesis promoter composition according to claim 1, further comprising one or more pharmaceutically acceptable carriers. 제2항에 있어서, 약제학적 제제의 형태로 제형화된 혈관생성촉진제 조성물.The angiogenesis promoter composition according to claim 2 formulated in the form of a pharmaceutical formulation. 제3항에 있어서, 약제학적 제제가 정제, 경질 또는 연질 캅셀제, 액제, 현탁제, 주사용 용액 또는 현탁액, 연고제, 크림제, 겔제 또는 로숀제 형태인 혈관생성촉진제 조성물.4. The angiogenesis composition according to claim 3, wherein the pharmaceutical formulation is in the form of tablets, hard or soft capsules, solutions, suspensions, injectable solutions or suspensions, ointments, creams, gels or lotions. 제4항에 있어서, 약제학적 제제가 G1G1분획 100mg 내지 2g을 함유하도록 제형화된 단위제형인 혈관생성촉진제 조성물.The angiogenesis composition according to claim 4, wherein the pharmaceutical formulation is in unit dosage form formulated to contain 100 mg to 2 g of a G1G1 fraction. 제5항에 있어서, 약제학적 제제가 G1G1분획 150mg 내지 1g을 함유하도록 제형화된 단위제형인 혈관생성촉진제 조성물.6. The angiogenesis promoter composition according to claim 5, wherein the pharmaceutical formulation is in unit dosage form formulated to contain 150 mg to 1 g of G1G1 fraction. 제1항에 있어서, 창상치료제로 사용되는 혈관생성촉진제 조성물.The angiogenesis promoter composition according to claim 1, which is used as a wound healing agent. 제1항에 있어서, 수술부위의 회복제로 사용되는 혈관생성촉진제 조성물.The angiogenesis promoter composition according to claim 1, which is used as a repair agent for a surgical site. 알로에의 전체 잎의 외피를 제거하여 겔 분획만을 분리하고, 겔 분획을 동결건조시킨 후, 증류수에 용해시키고, 탄소수 1 내지 4의 알콜 용매을 가하여 정치시키고 원심분리하여 침전을 제거한 후, 상등액으로부터 알콜 추출용매를 증발시켜 제거하고 잔류물을 동결건조시킴을 특징으로 하여, 알로에의 글리코펩타이드 및 저분자 물질 G1G1 분획을 제조하는 방법.The outer skin of the whole leaf of aloe was removed to separate only the gel fraction, and the gel fraction was lyophilized, dissolved in distilled water, left to stand by adding an alcohol solvent having 1 to 4 carbon atoms, and centrifuged to remove the precipitate, followed by alcohol extraction from the supernatant. A process for preparing the glycopeptide and low molecular weight G1G1 fraction of aloe, characterized by evaporating off the solvent and lyophilizing the residue. 제9항에 있어서, 탄소수 1 내지 4의 알콜 용매로 에탄올을 사용함을 특징으로 하는 방법.10. The process according to claim 9, wherein ethanol is used as the alcohol solvent having 1 to 4 carbon atoms. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940010142A 1994-05-09 1994-05-09 Angiogenesis stimulating composition KR0156593B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019940010142A KR0156593B1 (en) 1994-05-09 1994-05-09 Angiogenesis stimulating composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019940010142A KR0156593B1 (en) 1994-05-09 1994-05-09 Angiogenesis stimulating composition

Publications (2)

Publication Number Publication Date
KR950031101A true KR950031101A (en) 1995-12-18
KR0156593B1 KR0156593B1 (en) 1998-11-16

Family

ID=19382756

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940010142A KR0156593B1 (en) 1994-05-09 1994-05-09 Angiogenesis stimulating composition

Country Status (1)

Country Link
KR (1) KR0156593B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100352148B1 (en) * 1999-11-26 2002-09-12 주식회사 유니젠 Compositions for angiogenesis and preventing and treating arthritis comprising β-sitosterol

Also Published As

Publication number Publication date
KR0156593B1 (en) 1998-11-16

Similar Documents

Publication Publication Date Title
Sikiric et al. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice
AU601423B2 (en) Dual phase solvent carrier system
KR920004395A (en) Hydrogenated Rapamycin Derivatives
KR910011277A (en) Active ingredient concentrates from Ginkgo bilona leaves and novel active ingredient mixtures, preparation methods thereof and agents containing said active ingredient concentrate or said active ingredient mixture
Drosos et al. Humeomics: A key to unravel the humusic pentagram
US20070077317A1 (en) Olive kernel composition containing absorption promoters, antioxidants, and anti-inflammatory agents
HU228799B1 (en) Tanacetum parthenium extract
US5422393A (en) Natriuretic hormone
KR950031101A (en) Angiogenesis promoter composition
BR122012018280B8 (en) pharmaceutical composition comprising human luteinizing hormone and sucrose
CH654210A5 (en) PROCEDURE TO GET PREPARED metabolically INCOME OBTAINED FROM YEAST OF ANY KIND.
Levine et al. Enhancement of experimental allergic encephalomyelitis by adrenalectomy.
Ali et al. Effect of extract of Rhazya stricta, a traditional medicinal plant, on rat brain tribulin
CN1326343A (en) Agent for lowering prolactin
KR960700064A (en) Prostate Extract Supplemented with Zinc
KR960021053A (en) Epithelial cell damage treatment composition
CN1305866C (en) Method of extracting phenolic components from chinese medicine red sage root and its freeze dried powder injection agent
Moszkowska et al. Separation of pineal extracts by gelfiltration V. location by paper chromatography of a sheep pineal principle inhibiting hypophyseal gonadotropic activity
Muhamad Ibrahim et al. Swertiamarin ointment: a traditional approach in cutaneous wound healing
WO2007066355B1 (en) Processes for the preparation and estimation of enriched calcitriol containing extracts from cestrum diurnum and compositions thereof
Currie et al. Identification and purification of factor A-GHRH from hypothalami which releases growth hormone
KR940000110A (en) Herbal Extract Composition with Anti-Acquired Immune Deficiency Virus Effect and Its Extraction Method
KR970009802A (en) Method of preparing a pharmaceutical extract from the preparation and a pharmaceutical composition for the prevention and treatment of liver disease containing the extract
WO1990000394A1 (en) Natriuretic hormone
KR960000244A (en) Extract of Philiostigma Tonninji, Method of Use thereof, and Composition Comprising the Same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120607

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20130627

Year of fee payment: 16

EXPY Expiration of term